AWM
BCLI

AE Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

AE Wealth Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-961
Closed -$2.89K – 2060
2023
Q3 		$2.89K Buy
+961
New +$21.9K ﹤0.01% 1934

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AE Wealth Management's BCLI Position: Q4 2023 in Review

AE Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 961 shares — an estimated $2.89K sold.

AE Wealth Management first reported a position in BCLI in Q3 2023 and held it in 1 quarter. The position peaked at $2.89K in Q3 2023. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • AE Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • AE Wealth Management sold 961 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $2.89K.
  • AE Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2023 and held it in 1 quarter.
  • AE Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $2.89K in Q3 2023.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on AE Wealth Management's 13F filing for Q4 2023, filed 14 Feb 2024.